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Abstract Nuclear receptors (NRs) have the ability to elicit two different kinds of responses, genomic and non-genomic.
Although genomic responses control gene expression by influencing the rate of transcription, non-genomic effects
occur rapidly and independently of transcriptional regulation. Due to their anucleate nature and mechanistically
well-characterized and rapid responses, platelets provide a model system for the study of any non-genomic effects
of the NRs. Several NRs have been found to be present in human platelets, and multiple NR agonists have been
shown to elicit anti-platelet effects by a variety of mechanisms. The non-genomic functions of NRs vary, including
the regulation of kinase and phosphatase activity, ion channel function, intracellular calcium levels, and production
of second messengers. Recently, the characterization of mechanisms and identification of novel binding partners of
NRs have further strengthened the prospects of developing their ligands into potential therapeutics that offer
cardio-protective properties in addition to their other defined genomic effects.
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1. Introduction
Nuclear receptors (NRs) represent the family of mammalian proteins
associated with the transcriptional regulation in human tissues and
include the androgen receptor (AR), oestrogen receptor (ER), glucocor-
ticoid receptor (GR), farnesoid X receptor (FXR), liver X receptor
(LXR), peroxisome proliferator-activated receptors (PPARs), retinoic
acid receptor (RAR), retinoid X receptor (RXR), and the vitamin D
receptor (VDR). Upon activation by their lipophilic ligands, NRs regulate
several fundamental biological processes, such as cell proliferation, differ-
entiation, metabolism, and homeostasis (Table 1).1,2 Any deviation from
their normal function can lead to the pathological manifestations, such as
cancer, diabetes, arthritis, and obesity.3
NRs have the ability to function in both genomic and non-genomic ways.
Whilst historically associated with the regulation of transcription and
control of gene expression (genomic), more recently non-genomic roles
for the NRs have been identified that occur independently of transcrip-
tional regulation. Unlike the genomic functions, which can occur over
minutes or hours, these events occur in the time frame of seconds to a
few minutes, which is considered too rapid to be attributed to the bio-
synthesis of mRNA or protein, and is often unaffected by the inhibitors
of transcription or translation.4 The non-genomic functions of NRs
vary5–7 and whilst it is thought these functions are initiated by physical
interactions of NRs with cofactors and binding partners that initiate rapid
signalling events, the exact mechanisms are not well understood. One
possible explanation is that the cellular localization of NRs influences the
availability of cofactors and substrates, which leads to varying combina-
tions of binding partner interactions. For instance, localization of NRs to
the cytosol, plasma membrane, or other intracellular organelles such as
mitochondria increases the likelihood of initiation of non-genomic
effects, whilst genomic functions may be restricted to when NRs are
localized in the nucleus.8–11 The formation of different multi-protein sig-
nalling complexes with different localization and distribution patterns
across different cell types could offer a high degree of cell and tissue
selective action for the NRs but as of yet these are poorly defined.10,11
Given the underlying differences between the genomic and non-
genomic activities, non-genomic effects are more easily observed in cell
types that lack a functional nucleus such as erythrocytes and platelets.
Emerging evidence indicates that platelets are also involved in roles
beyond those described in haemostasis and thrombosis. For instance,
granule secretion following platelet activation results in the release of an
array of chemokines, cytokines, growth factors, anti-inflammatory fac-
tors, and several other biologically active molecules into the vicinity of
injured tissues that contribute towards the progression of numerous dis-
eases including inflammatory conditions (e.g. atherosclerosis and rheu-
matoid arthritis),12,13 type 2 diabetes,14 and cancer cell metastasis).15
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..Thus, platelets are highly active cells with diverse functions despite lack-
ing genomic DNA. Although devoid of a nucleus, platelets still contain
different forms of RNA (mRNA, rRNA, tRNA, and miRNA) and compo-
nents of the transcription and translation machinery that are derived
from megakaryocytes during thrombopoiesis.16 There is a growing con-
sensus that these RNAs are not subjected to a random transfer by mega-
karyocytes but are specifically sorted and are competent for translation
within platelets.17,18 Moreover, there is evidence to suggest that platelet-
derived microparticles may deliver platelet mRNAs into other nucleated
cells, such as monocytes and endothelial cells, where they then undergo
translation.19 Components of this transcription machinery found to be
present inside platelets include the intracellular NRs. Due to their anu-
cleate nature and mechanistically well characterized and rapid responses,
such as aggregation and adhesion, platelets provide an excellent model
system to study the acute non-genomic effects of the NRs.20,21
2. NRs are acute regulators of
platelet function
On the basis of the mechanisms of action in the nucleated cells, NRs are
classified into two classes: type I or the steroid hormone receptors and
type II or the non-steroid receptors. Platelets are known to express
both the classes of these receptors. This includes the AR,22,23 ER,22,24–26
GR,27,28 FXR,29,30 LXR,30,31 PPARs,32–40 RAR,41 RXR,42,43 and VDR.44,45
Both natural and synthetic ligands for these NRs have been shown to
alter platelet function through a variety of mechanisms as described
below and summarized in Table 2.
3. Type I NRs
Mechanisms by which type I NRs (GR, ER, and AR) regulate platelet
functions are poorly understood. This might be attributed to the varia-
tions in the plasma levels of the steroid hormones targeting these NRs
(especially in females and under certain pathological conditions).49–51
This might lead to an inaccurate assessment of the role type I NRs play in
modulating platelet functions in acute vs. chronic studies and might
account for the existing contradictory published data. The effects of
ligands of type 1 NRs on platelet function currently published are
described below.
3.1 Glucocorticoid receptor
GRs are activated by glucocorticoid and anti-inflammatory hormones
that regulate inflammation and glucose homeostasis.52 Prednisolone, a
synthetic glucocorticoid derived from cortisol, has been shown to
..............................................................................................................................................................................................................................
Table 1 NRs and their biological functions
Nuclear
receptor
Ligands Biological function
GR Natural: glucocorticoid Lipolysis
Glucose metabolismSynthetic: RU38486, A348441
ER Natural: oestrogen, including oestrone (E1), oestradiol (E2) and
oestriol (E3)
Development of the female reproductive system and
secondary sexual characteristics
AR Natural: dihydrotestosterone, testosterone Development of the male reproductive system and secondary
sexual characteristicsSynthetic: mibolerone
LXR Natural: oxysterols Lipid and carbohydrate metabolism
Synthetic: T0901317, GW3965
FXR Natural: bile acids Bile acid homeostasis
Synthetic: GW4064, farnesol, CDCA
PPARa Natural: polyunsaturated fatty acids Fatty acid oxidation and lipid metabolism
Synthetic: fibrates (gemfibrozil, fenofibrate, clofibrate)
PPARb Natural: unsaturated/saturated fatty acids, eicosanoids,
prostacyclin
Cholesterol metabolism
Synthetic: GW501516
PPARc Natural: 15-deoxy-12, 14 prostaglandin J2 (15d-PGJ2) Lipid and glucose metabolism
Synthetic: thiazolidinedione (ciglitazone, pioglitazone,
rosiglitazone)
RAR Natural: atRA Cell growth, differentiation and organogenesis
RXR Natural: 9-cis-retinoic acid, docosahexaenoic acid Cellular proliferation and differentiation, glucose, fatty acid and
cholesterol metabolismSynthetic: methoprene acid, rexinoids (LG100268)
VDR Natural: calcitriol Calcium homeostasis, cell proliferation and differentiation
Synthetic: maxacalcitol, calcipotriol
646 A.J. Unsworth et al.
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Table 2 A summary of NRs identified in platelets and their modes of action
Nuclear
receptor
Ligands Effect on platelet function Mechanisms of action
GR27,28 • Prednisolone • Negative regulation of platelet secondary
mediator regulated effects (ADP and TXA2)
• In vitro
• Human platelets
Mechanism is unknown
ER25,26 • Oestrogen—oestrone (E1),
oestradiol (E2) and oestriol (E3)
• Reduction in platelet responsiveness how-
ever, conflicting results exist
• In vitro, ex vivo, in vivo
• Human, mouse platelets
Mechanism is unknown
AR46–48 • Testosterone
• Dihydrotestosterone
• Potentiation of platelet aggregation
• In vitro and ex vivo
• Human and rat platelets
Mechanism is unknown
LXR31 • GW3965
• T0901317
• 24(S)-OH-cholesterol
• 27-OH-cholesterol
• Inhibition of platelet function and thrombosis
• In vitro and in vivo
• Human and mouse platelets
• Conversion of platelets to the procoagulant
state
• In vitro
• Human platelets
• Reduced phosphorylation of early GPVI sig-
nalling components—Syk, LAT and PLCc2
Increase LXR-Syk and LXR-PLCc2
interaction
• Formation of coated platelets, including PS
exposure, mitochondrial membrane
depolarization
(see Figure 1)
FXR29 • GW4064
• Chenodeoxycholic acid
• 6a-ethyl-chenodeoxycholic acid
• Inhibition of platelet function, thrombosis and
haemostasis
• In vitro and in vivo
• Human, mouse platelets
• Cyclophillin D-dependent formation of
coated platelets and closure of surface
integrins
• Associated with PS exposure and mitochon-
drial membrane depolarization
• Augmented cGMP levels which promote
PKG activity and phosphorylation of VASP
S239
(see Figure 1)
• Conversion of platelets to the procoagulant
state
• In vitro
• Human platelets
PPARa33 • Fenofibrate
• Statins
• Inhibition of platelet function
• In vitro
• Human, mouse platelets
• Increase in cAMP levels
• PPARa–PKCa interaction and attenuation of
PKCa
(see Figure 2)
PPARb/d35 • GW0742
• L-165041
• Inhibition of platelet function
• In vitro
• Human, mouse platelets
• Increase in cAMP levels
• PPARa–PKCa interaction and attenuation of
PKCa (see Figure 2)
PPARc38,39 • 15d-PGJ2
• Thiazolidinediones (rosiglitazone,
ciglitazone, pioglitazone)
• Inhibition of platelet function, thrombosis and
haemostasis
• In vitro and in vivo
• Human, mouse platelets
• Inhibition in phosphorylation of Syk and LAT
to reduce GPVI signalling
• Reduced PPARc–Syk and PPARc–LAT inter-
action upon PPARc ligand treatment
• Negative regulation of integrin aIIbb3 out-
side-in via up-regulation of PKA activity and
inhibition b3 phosphorylation
(see Figure 2)
RAR41 • atRA • Inhibition of cytoskeletal rearrangements and
platelet spreading
• In vitro
• Human platelets
Disruption of RARa–Arp2/3 interactions. (see
Figure 3)
Continued
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attenuate platelet function.27,28 Prednisolone-treated platelets displayed
reduced aggregation and thromboxane B2 (TxB2) release in response to
stimulation by either ADP or the TxA2 mimetic U46619, which was
reversed following treatment with a GR antagonist mifepristone.27 This
inhibition was not found to be associated with up-regulation of cyclic
nucleotides—cyclic adenosine monophosphate (cAMP) or cyclic guano-
sine monophosphate (cGMP), key inhibitory mediators of platelet activ-
ity.28 Platelet adhesion and thrombus formation under flow on collagen
in vitro were also found to be diminished following prednisolone treat-
ment which is likely an outcome of reduced platelet responses to ADP
and TxA2, secondary mediators of platelet activation that support plate-
let adhesion and thrombus growth.28 Prednisolone has also shown to
modulate platelet–monocyte interactions following stimulation by ADP,
which is attributed to an attenuation of platelet activity and not to inhibi-
tion of monocytes.28 It should be noted, however, that alternative GR
ligands—dexamethasone, fludrocortisone, and triamcinolone have not
been shown to elicit anti-platelet effects under the experimental condi-
tions used in these studies.27,28 This difference in activation is thought to
be due to the formation of a heterodimeric complex between GR and
the mineralocorticoid receptor that is susceptible to the differential acti-
vation by specific receptor ligands. The mechanism underlying the nega-
tive regulation of secondary mediator signalling by GR and its ligand
prednisolone is yet to be fully explored although evidence suggests that
this might be mediated through the regulation of signalling events down-
stream of the P2Y12 receptor.
28
3.2 Oestrogen receptor
Oestradiol-17b (E2) and ERs are not only well known for their role in
reproductive and sexual development but also known to directly influ-
ence cardiovascular health.53 Human platelets have been shown to
express ERb but not ERa.22 Studies investigating the effects of several
forms of oestrogen, including oestrone (E1), oestradiol (E2), and oestriol
(E3) on platelet function have yielded conflicting results. In one study,
acute treatment of platelets ex vivo with either E1 or E3 was found to
increase aggregation to adrenaline or ADP.24 In contrast, chronic treat-
ment with oestrogen, in an alternative study, investigating oestrogen
replacement therapy (3 months), found a significant decrease in
adrenaline-induced platelet aggregation and ATP release in patients
receiving the therapy compared to the control groups.25 In further sup-
port of this, chronic treatment with high levels of oestradiol in mice was
found to cause a marked decrease in platelet responsiveness both ex vivo
and in vivo, with both an increase in bleeding time and resistance to
thromboembolism being observed.26 However, it is important to note
these effects on platelet reactivity are due to modulation of expression
of platelet proteins (such as b1 tubulin) during haematopoiesis that then
alter platelet production and activation,26 rather than a direct non-
genomic effect on platelet function.
3.3 Androgen receptor
The AR, activated by either testosterone or dihydrotestosterone, has
been identified in platelets,22 but little is known regarding its potential
role in the regulation of platelet function. Some studies have specified
that the aggregation response of platelets isolated from male rats was
stronger in comparison to female rats owing to higher levels of andro-
genic steroids46 as platelet aggregation was found to be reduced follow-
ing castration in male rats and the reversal of these effects following
treatment with testosterone.47 Pilo et al. also reported that acute treat-
ment of rat or human PRP with testosterone potentiates platelet aggre-
gation induced by ADP, adrenaline, collagen, arachidonic acid, and
calcium ionophore indicating its rapid non-genomic responses.48 Two
independent studies also confirmed that testosterone causes a significant
increase in TXA2 receptor density on the platelet surface, thereby, indi-
rectly increasing platelet responsiveness.54,55 However, inhibition of pla-
telet aggregation has also been observed following treatment with
testosterone, although this was found to be attributed to endothelial
NO synthesis and therefore not necessarily a direct effect of testoster-
one on the platelet AR and platelet activity.23
4. Type II NRs
4.1 Liver X receptor
LXR receptors are implicated in the regulation of fatty acid, cholesterol,
and glucose homeostasis. Endogenous ligands for the LXR receptors
include oxysterols such as 22(R)-hydroxycholesterol, 24(S)-hydroxy-
cholesterol, 27-hydroxycholesterol, and several synthetic ligands includ-
ing GW3965 and T0901317 have also been developed.56,57 Like some of
the other NRs, ligands for LXR have been described to have anti-
inflammatory and atheroprotective properties, and LXRb has been
shown to be expressed in platelets.31 Treatment of platelets with the
..............................................................................................................................................................................................................................
Table 2 Continued
Nuclear
receptor
Ligands Effect on platelet function Mechanisms of action
RXR42,43 • 9-cis-retenoic acid
• Methoprene acid
• Docosahexaenoic acid
• Inhibition of platelet function, thrombosis and
haemostasis
• In vitro and in vivo
• Human, mouse platelets
• RXR–Gq interaction and negative regulation
of Rac activation to inhibit GPCR-mediated
platelet activation
• Up-regulation of PKA activity and phosphory-
lation of VASP S157 in cAMP- and NFjb-
dependent manner (see Figure 3)
VDR45 • Vitamin D and its metabolites • Low vitamin D plasma levels cause high mean
platelet volume, a marker of platelet
hyperactivity
• In vivo
• Human platelets
Mechanism is unknown
648 A.J. Unsworth et al.
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..synthetic agonist GW3965 results in inhibition of platelet activation, with
attenuation of aggregation, calcium mobilization, secretion and integrin
activation observed following stimulation by collagen, collagen-related
peptide (CRP-XL; a GPVI collagen receptor-specific agonist), and throm-
bin. In analysis of thrombosis, GW3965-treated mice were also found to
form smaller, less stable thrombi following laser injury of the cremaster
arterioles. LXR has also been shown to interact with several compo-
nents of the GPVI signalling pathway following treatment with GW3965,
including Syk and PLCc2, and treatment with LXR ligands is associated
with decreased phosphorylation and signalling.31 In support of this,
another study reported the ability of endogenous LXR ligand 22(R)-OH-
cholesterol [but not its stereoisomer 22(S)-OH-cholesterol] to inhibit
collagen-induced platelet aggregation and shape change.58
During thrombus formation, two distinct populations of platelets
appear, coaggregated platelets, which support thrombus growth, and
loosely attached procoagulant platelets that expose phosphatidylserine
and support coagulation. Conversion to the procoagulant state is also
thought to be associated with platelet hyper-reactivity, a trait often
observed in patients with an increased risk of thrombosis including those
with pathological conditions, such as hyperlipidaemia, obesity, and high
plasma cholesterol levels. Treatment of platelets with LXR ligands,
GW3965 and T0901317, and natural ligands, 27-OH-cholesterol and
24-(S)-hydroxyl-cholesterol, has also been shown to cause platelet
inhibition to several agonists through the conversion of platelets to pro-
coagulant coated platelets.39 LXR ligand-stimulated coated platelets not
only expose phosphatidylserine at the membrane surface but also retain
high levels of fibrinogen (which is converted to fibrin) and other alpha
granule components at the platelet membrane (Figure 1). Conversion to
the coated platelet state is thought to support coagulation but renders the
platelet, through closure of integrin aIIbb3, unresponsive to platelet ago-
nists, which was also observed in platelets following treatment with LXR
agonists. The mechanism by which this occurs in LXR agonist (GW3965)-
Figure 1 LXR and FXR ligands negatively regulate platelet function through inhibition of platelet signalling and formation of procoagulant coated platelets.
Treatment of platelets with LXR ligands results in reduced tyrosine phosphorylation of key GPVI signalling molecules Syk, LAT and PLCc2. An increase in
the level of LXR–Syk and LXR–PLCc2 interaction is also observed. Exposure to LXR ligands also renders platelets into a procoagulant state characterized
by the exposure of phosphatidylserine and a-granule contents on the platelet surface, which is coupled with depolarization of the mitochondrial membrane
potential, reduced calcium mobilization and down-regulation in the affinity of integrin aIIbb3, ultimately resulting in the inhibition of platelet aggregation.
Similarly, incubation of platelets with FXR ligands can lead to platelet swelling and conversion to procoagulant coated platelets which is dependent on cyclo-
phillin D activity. Additionally, FXR ligands are able to increase cGMP levels that promotes the activity of PKG and phosphorylation of VASP S239 and
thereby suppresses platelet activation.
Non-genomic effects of nuclear receptors 649
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.treated platelets appears to be via deregulation of intracellular calcium sig-
nalling, depolarization of the mitochondrial membrane potential inde-
pendently of cyclophillin D, and generation of reactive oxygen species
(ROS).39 It is therefore possible that the platelet dysfunction observed in
patients with high cholesterol, hyperlipidaemia, metabolic syndrome, and
obesity could be attributed to altered LXR signalling in platelets.
4.2 Farnesoid X receptor
The bile acid receptor, FXR, which is recognized to regulate bile acid and
cholesterol homeostasis has been identified in both human and mouse
platelets. Treatment of platelets with synthetic FXR ligand GW4064 was
found to cause a decrease in sample turbidity,29,39 which was later con-
firmed to be due to platelet swelling and conversion of platelets to a pro-
coagulant state, forming coated-platelets.39 Synthetic and natural FXR
ligand-dependent formation of coated platelets, prior to platelet agonist
stimulation, results in phosphatidylserine exposure, retention of fibrino-
gen, fibrin and alpha granule proteins at the platelet surface, cyclophillin
D-dependent depolarization of the mitochondrial membrane, sustained
calcium signalling, generation of reactive oxygen species, and closure of
integrins at the platelet surface.39 This closure of platelet integrins is
believed to underlie the observed reduction in platelet aggregation to
platelet agonists. Although the initial kinetics of thrombus formation was
increased in mouse in vivo models of thrombosis, consistent with a pro-
coagulant state, thrombus stability was significantly decreased following
treatment with the FXR ligand GW4064, in agreement with reduced
integrin function, which is essential for stable thrombus formation.29
Treatment with FXR ligands was also found to be associated with an
increase in intracellular levels of cGMP in platelets, indicative of deregula-
tion of intracellular signalling (Figure 1). Platelets from FXR-deficient mice
were found to be unresponsive to the actions of FXR agonists, confirm-
ing the selective non-genomic actions of these ligands to the FXR.29
4.3 Peroxisome proliferator-activated
receptors
PPARs represent three NR isoforms, PPARa, PPARb, and PPARc, which
are involved in cell development, differentiation, cholesterol and fatty
acid metabolism, and glucose homeostasis. All three isoforms of PPARs,
upon binding to their ligands, are capable of heterodimerizing with the
RXR43 and all have been identified to have acute, non-genomic, negative-
regulatory effects in human platelets.
4.3.1 PPARa
The treatment of platelets with ligands of PPARa such as fenofibrate or
statins (simvastatin) has been shown to inhibit ADP-stimulated platelet
activation by increasing intracellular levels of cAMP via a PPARa-depend-
ent mechanism. In support of this, the observed inhibition can be reversed
following treatment with PPARa antagonist GW6471.33 This dependence
on PPARa is further reinforced by experiments that show fenofibrate-
induced inhibition of platelet activation and increased bleeding time in
mice does not occur in mice deficient in PPARa. Fenofibrate-induced
inhibition of platelet activity was found to be mediated through up-regula-
tion of cAMP levels via inhibition of PKCa, a key mediator of platelet signal-
ling, through interaction between PPARa and PKCa. This interaction is
believed to sequester PKCa away from its substrates and thereby attenu-
ates platelet functions (Figure 2).33 These findings identify PPARa as a key
mediator of statin and fenofibrate-mediated anti-platelet activity.
Figure 2 Non-genomic regulation of platelets by PPAR ligands. PPARa ligands, fenofibrate or simvastatin and PPARb/d ligands, GW0742 and L-165041
cause a reduction in intracellular calcium mobilization and platelet activation. This inhibition was found to be mediated by augmented levels of cAMP and
attenuation of PKCa through its interaction with PPARa or PPARb/d, which limits its availability to facilitate signalling downstream of PKCa. Treatment with
PPARc ligands inhibits platelet activation to collagen through an inhibition in phosphorylation of Syk and LAT that mediate signalling initiated by the collagen
receptor GPVI. Negative regulation of integrin aIIbb3 outside-in signalling was observed as an outcome of up-regulation of PKA activity and inhibition in phos-
phorylation of b3 and subsequent downstream signalling molecules—Syk, PLCc2, PKC substrates, FAK and PI3K substrates.
650 A.J. Unsworth et al.
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4.3.2 PPARb/d
Studies using synthetic ligands for PPARb/d, GW0742, and L-165041
have identified negative-regulation of platelet activity arbitrated through
PPARb/d. Incubation with PPARb/d ligands showed inhibition of platelet
aggregation and mobilization of intracellular calcium following stimula-
tion by several platelet agonists.34 PPARb/d can also be activated by the
prostaglandin PGI2, and therefore some of the inhibitory effects of PGI2
on platelet activity could also be mediated through PPARb/d in addition
to the prostaglandin IP receptor but this has yet to be tested.34 Similar to
PPARa, treatment of platelets with synthetic ligands of PPARb/d have
been shown to cause an increase in intracellular cAMP levels and PKCa
has been identified as a potential binding partner of the receptor indicat-
ing a plausible mechanism by which PPARb/d regulates platelet reactivity
(Figure 2)35 PPARb/d ligands have been shown to decrease plaque for-
mation and attenuate the progression of atherosclerosis.59 As platelets
play a key role in the initiation and progression of atherosclerosis, anti-
platelet effects of PPARb/d ligands may partly explain such observed
reduction in the development of atherosclerosis.
4.3.3 PPARc
PPARc is the most widely studied of the PPAR family in platelets. This is
mainly because of its direct involvement with numerous cardiovascular
diseases, such as diabetes mellitus, atherosclerosis, and thrombosis.60–62
Synthetic ligands of PPARc, the thiazolidinediones (pioglitazone, rosigli-
tazone, lobeglitazone, etc.), are currently in use for the treatment of
type 2 diabetes and have been observed clinically to have cardio-
protective properties. The anti-platelet activity of PPARc ligands may
provide a mechanistic basis that in part underlies these observations. For
example, a clinical study conducted on patients suffering from coronary
heart disease and taking rosiglitazone reported its long-term antiplatelet
effects with down-regulation of P-selectin exposure and granule secre-
tion.63 Exposure of platelets ex vivo to the endogenous (15d-PGJ2) and
synthetic (rosiglitazone and ciglitazone) ligands of PPARc has been
shown to inhibit platelet activation to a variety of platelet agonists,
including the G-protein-coupled receptor agonists—thrombin and
ADP,32 GPVI agonists—collagen and CRP-XL,38 and the adhesion recep-
tor integrin aIIbb3 agonist fibrinogen.
39 PPARc ligands, 15d-PGJ2 or rosi-
glitazone, inhibit platelet responses including granule secretion and TxB2
synthesis in response to thrombin or ADP.32 These ligands have also
been shown to reduce GPVI agonist-stimulated platelet aggregation,
granule secretion, and mobilization of intracellular calcium, via inhibition
of early GPVI signalling events such as phosphorylation of Syk and
LAT.38 PPARc was also found to interact with Syk and LAT upon stimu-
lation with collagen in the absence of PPARc ligands; however, this inter-
action is disrupted on treatment with PPARc ligands. These ligands have
also been shown to inhibit integrin aIIbb3 outside-in signalling through
the up-regulation of PKA activity. PPARc ligand-dependent inhibition of
b3 phosphorylation and other downstream signalling molecules of the
integrin aIIbb3 signalling pathway including Syk, PLCc2, PKC, FAK, and
PI3K indicates several different mechanisms by which PPARc ligands can
negatively regulate platelet function.39 This negative regulation of plate-
let activity has also been found to result in an inhibition of thrombus for-
mation in vivo in animal models following treatment with another
synthetic PPARc ligand, pioglitazone.37
PPARc is also implicated in a mechanism by which statins mediate
acute anti-platelet effects.33,36 Treatment of human whole blood with
simvastatin has been shown to cause a reduction in platelet aggregation
to ADP. This inhibition of platelet function was attributed to an increase
in intracellular cAMP levels which is associated with PPARc activity and
its association with and inhibition of PKCa (Figure 2).33 In addition, treat-
ment of platelets with simvastatin was also found to inhibit collagen-
induced platelet aggregation, granule secretion, integrin activation, and
Ca2þ mobilization in a PPARc-dependent manner. This was found to
involve PPARc-dependent mediation of mitogen-activated protein kin-
ase (MAPKs, i.e. p38 MAPK, ERK) signalling by increasing association of
MAPKs with the receptor resulting in an increase of cAMP formation
that is associated with an increase in VASP Ser157 phosphorylation and
inhibition of Akt phosphorylation.36
4.4 Retinoic acid receptor
RARs play a critical role in numerous biological processes, including devel-
opment, reproduction, immunity, organogenesis, and homeostasis.64 Three
forms of RAR exist—RARa, RARb, and RARc. Of these, RARa is ubiqui-
tously distributed and has been reported to be robustly expressed in human
platelets, whilst the other two isoforms have tissue-specific distribution.65
RARs are activated by retinoids which are metabolites of vitamin A and sev-
eral synthetic ligands also exist.64 In platelets, RARa has been observed to
directly interact with actin-related protein-2/3 complex (Arp2/3) subunit 5
(Arp2/3s5) which is required for the regulation of platelet cytoskeletal proc-
esses. Treatment of platelets with the endogenous RARa ligand all-trans-
retinoic acid (atRA) disrupts the RARa–Arp2/3 interactions resulting in an
inhibition of both cytoskeletal rearrangements and platelet spreading (Figure
3).41 Recent developments have reported that RARa is capable of regulat-
ing protein synthesis (including microtubule-associated protein-1 light chain
3 beta 2) in human platelets by binding to a subset of mRNAs and blocking
translation. Schwertz et al.66 found that platelets treated with RARa ligand
atRA for several hours displayed significantly altered levels of protein syn-
thesis compared to controls.
4.5 Retinoid X receptor
RXR is regarded as one of the most important receptors in this superfam-
ily. Most likely due to its ability to interact with almost a quarter of the
known human NRs (PPAR’s, LXR, FXR, PXR, etc.) and form hetero-
dimers,67 although, the presence of RXR homodimers has also been
reported.68 RXR is well characterized and is involved in the regulation of
some of the most vital and fundamental biological processes including cell
proliferation, differentiation and death, haematopoiesis, metabolism (glu-
cose, fatty acid, and cholesterol), and pattern formation during embryo-
genesis.69 Human platelets have been shown to express RXRa and RXRb
(but the presence or absence of RXRc has not been established) and are
known to form heterodimers with PPARa, PPARc, and LXR in platelets.43
Treatment of platelets with the endogenous ligand of RXR, 9-cis-retinoic
acid or the synthetic ligand, methoprene acid, results in inhibition of plate-
let function stimulated by Gq-coupled GPCRs—ADP, U4661942 or
thrombin and also, GPVI-mediated platelet activation via stimulation by
collagen or CRP-XL.43 Regulation of GPCR-mediated platelet activation
by RXR has been associated with its binding to Gaq in a ligand-dependent
manner that inhibits Gq-induced Rac activation and intracellular Ca2þ
mobilization.42 Exposure to RXR ligands has also been shown to reduce
integrin aIIbb3 outside-in signalling and cytoskeletal rearrangements. The
negative regulation of several platelet activation pathways and processes
results in robust inhibition of thrombosis and haemostasis in vivo.43 As seen
with several other NRs, treatment with RXR ligands has also been shown
to up-regulate PKA activity and VASP S157 phosphorylation via a process
that is dependent on cAMP and also involves NFjb (Figure 3). This sug-
gests that RXR ligands inhibit platelet function using several different
Non-genomic effects of nuclear receptors 651
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.inhibitory mechanisms which is likely to reflect its ability to form hetero-
dimers with several different NRs in platelets.43
4.6 Vitamin D receptor
The VDR is another ligand-activated transcription factor that mediates
the actions of vitamin D and its metabolites. VDR is also known to form
a heterodimer with the RXR and regulate calcium homeostasis, cell
growth and differentiation, detoxification of xenobiotics, and modulation
of adaptive and innate immunity.70 Although anticoagulant effects of vita-
min D have been reported and VDR signalling has been characterized in
monocytes and vascular cells, the role for the VDR in platelet function
remains unknown. Human platelets have been found to express the
VDR. Biochemical fractionation studies along with immuno-electron
microscopy analysis identified the VDR to be localized in the soluble and
mitochondrial compartment.44 Although little is known about the role
for vitamin D and the VDR in platelet function, a patient study identified
a strong association between low vitamin D plasma levels and a high
mean platelet volume, a marker of platelet hyperactivity.45
5. Future perspectives
5.1 Could NRs offer anti-platelet
therapeutic targets?
The role of platelets in controlling haemostasis and initiating thrombosis
is well known. This makes them important therapeutic targets for the
treatment of cardiovascular diseases, particularly atherothrombosis.71
Despite significant advances in the development of antithrombotic thera-
peutics, they are associated with increased bleeding risk and their efficacy
is often compromised in patients suffering from several conditions, such
as hypertension and diabetes.11,72,73 Therefore, more refined and effec-
tive therapeutics that ensure a balance between the treatment of throm-
bosis and related complications is needed.
A key step forward would be using our current knowledge of the
molecular mechanisms governing platelet functions as the basis for the
development of more effective and safer anti-platelet therapies. Both
natural and synthetic ligands of NRs have been shown to exhibit non-
genomic effects to alter platelet function through a variety of mecha-
nisms, several of which appear to be shared by different NR family mem-
bers.21,74 For instance, RXR, FXR, PPARa, PPARb, and PPARc receptors
have been shown to be involved in the regulation of platelet inhibitory
signalling pathways by either increasing cAMP or cGMP levels or directly
modulating PKA/PKG activity. LXR and PPARc can negatively regulate
signalling downstream of the collagen receptor via interactions with dif-
ferent components of the GPVI signalling cascade. Given the potential of
heterodimeric receptor interactions between RXR and other NRs, the
idea of cross-talk becomes even more pronounced.43
5.2 Important considerations
Development of NRs as anti-platelet therapeutic targets requires a few
important considerations. First, the majority of the studies conducted so
far focus on understanding the acute effects of NR ligands on platelet
function; therefore, prior to further development it would be important
to study the implications of chronic exposure of platelets to NR ligands.
As NRs can regulate the expression of multiple genes, in various cell
types it is therefore highly likely that chronic exposure to NR ligands
could lead to systemic effects that might indirectly affect platelet
function.75
Figure 3 Inhibition of platelet function by RAR and RXR ligands is mediated through Arp2/3- and Gq-induced Rac activation and up-regulation of PKA
activity, respectively. RAR ligand atRA disrupts the RARa–Arp2/3 interaction resulting in an inhibition of cytoskeletal rearrangements and platelet spreading.
RXR ligands, 9cRA and methoprene acid inhibit platelet activation to a range of platelet agonists that include GPCR agonists (ADP, U46619 or thrombin)
and GPVI agonists (collagen or CRP-XL). Interaction of RXR with Gq and subsequent negative regulation of Rac activation is one of the probable explana-
tions for the reduction in GPCR-mediated platelet activation. These ligands have also been shown to up-regulate PKA activity in a cAMP- and NFjb-depend-
ent manner providing a more generalized mechanism of inhibition.
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..Secondly, although, there exists a clear distinction between genomic
and non-genomic effects, the existence of mRNA in platelets and their
limited ability to perform translation raises the possibility17,76 that there
are interactions between NRs and mRNA in platelets as in nucleated
cells. While the differences in the timescales taken to elicit these
genomic-like effect (hours) in comparison to the non-genomic effects
(minutes) still enable the differentiation between the two regulatory
mechanisms. Future studies should consider including inhibitors of trans-
lation which will help further differentiate between genomic and truly
non-genomic actions of these receptors, or indeed determine whether
NR ligands are capable of regulating protein translation in platelets and
characterizing whether any changes in protein levels have functional
effects. Schwertz et al.66 recently described such a mechanism demon-
strating RARa-dependent translational control in human platelets, which
resulted in the synthesis of several transcripts. Whether other NRs
(such as RXR and PPARs), identified in platelets, can also replicate such a
mechanism is still unknown. Moreover, evaluating whether genomic and
non-genomic regulation can facilitate cross-talk between the different
NRs in platelets requires further investigation. Development of NRs as
anti-platelet therapies would require careful balancing of their genomic
vs. non-genomic effects not only in platelets but also systemically.
Finally, it is important to note that NRs share a significant level of
structural similarity with each other, making them potentially promiscu-
ous in nature.77–81 Studies examining the genomic roles for the NRs
have shown, for example that 15d-PGJ2 is an endogenous ligand for
PPARc but it can also act as an antagonist for FXR82 and phytanic acid
has the ability to activate both PPARa and RXR.83 Guggulsterone is
regarded as an ER agonist but an antagonist to FXR, GR, and AR,84
although it does not appear to function as a non-genomic FXR antagonist
in platelets (LA.M, A.J.U, J.M.G, unpublished observations). Similarly,
LG100754 is a highly specific RXR: PPARc agonist while it acts as a
strong antagonist of RXR homodimers.85 This makes the selective tar-
geting of the NRs even more challenging and as such identification of
ligands that function in a receptor- and gene-specific manner is impor-
tant. Future work will be required to establish how and when NR heter-
odimers regulate platelet activity, and for each NR to establish its role in
normal physiological processes.
6. Conclusions
Platelets are known to act as direct contributors towards the progres-
sion of CVDs such as atherosclerosis,86 and their activity becomes con-
siderably enhanced in cases of hyperlipidaemia,87 obesity,88 diabetes
mellitus,89 or hypertension.90 Many NRs have been found to be
expressed in human platelets, including AR, ER, GR, FXR, LXR, PPARs,
RAR, RXR, and VDR, and agonists for several of these receptors have
been shown to elicit anti-platelet effects by a variety of mechanisms. NRs
including PPARs, LXR, and FXR ligands have all been reported to have
anti-atherosclerotic effects,91,92 coupling this with their anti-platelet
effects; there exists the possibility of a potentially new paradigm of treat-
ment that can target a range of pathophysiological conditions whilst also
offering platelet-targeted anti-thrombotic activity. Of FDA-approved
drugs, 13% function by targeting NRs for the treatment of numerous
pathological conditions93 (Table 3), and as a result, the effects on plate-
lets might be a likely consequence associated with the administration of
these drugs. It is important for the future development and use of NR
agonists that their acute and long-term effects on platelet function are
fully understood.
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